Dr. Kasner's research interests encompass the development and clinical application of novel therapeutic agents for AML and MDS. She has been involved in Phase I clinical trials investigating sirolimus combined with standard induction chemotherapy in newly diagnosed AML patients . Additionally, her work includes integrating electronic geriatric assessments and frailty screening to personalize treatment decisions for older adults with AML She specializes in hematologic malignancies, with a particular focus on acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and stem cell transplantation.
Margaret T. Kasner, MD, MSCE
Interim Director, Division of Hematologic Malignancies
Director Leukemia Program
Medical Director, Cancer Clinical Trials Operations, Sydney Kimmel Comprehensive Cancer Center
Professor
Contact Information
Honickman Center
1101 Chestnut Street
14th Floor
Philadelphia, PA 19107
Interim Director, Division of Hematologic Malignancies
Director Leukemia Program
Medical Director, Cancer Clinical Trials Operations, Sydney Kimmel Comprehensive Cancer Center
Professor
RESEARCH & CLINICAL INTEREST
Education
Medical School
University of Pennsylvania School of Medicine - 2001
Residency
Hospital of University of Pennsylvania (HUP)
Fellowship
Hospital of University of Pennsylvania (HUP)
Most Recent Peer-Reviewed Publications
- Radiate equity: the inclusion of radiation oncology and other specialties in lymphoma collaborative groups
- A smart pill bottle and text messaging intervention for promoting medication adherence in patients with chronic myeloid leukemia: a pilot study of txt4 TKI
- Targeting CD47: many misses; hopeful for a hit
- A Century of Hypomethylating Agent: A Remarkable Response to Azacitidine Monotherapy for Relapsed Acute Myeloid Leukemia – A Case Report
- North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era
Board Certifications
Medical Oncology
Internal Medicine
Hematology